Visterra’s (NASDAQ:VIST) lock-up period will expire on Wednesday, January 22nd. Visterra had issued 10,000,000 shares in its initial public offering on July 26th. The total size of the offering was $92,500,000 based on an initial share price of $9.25. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Separately, Zacks Investment Research upgraded Visterra from a “sell” rating to a “hold” rating in a report on Wednesday, December 25th.
Shares of Visterra stock opened at $7.50 on Tuesday. Visterra has a 52-week low of $3.80 and a 52-week high of $11.03. The firm’s 50-day moving average price is $7.67.
Visterra (NASDAQ:VIST) last announced its quarterly earnings results on Tuesday, October 22nd. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.08. The firm had revenue of $105.44 million for the quarter.
Institutional investors have recently made changes to their positions in the company. Boston Partners acquired a new stake in shares of Visterra during the 3rd quarter valued at about $5,067,000. FNY Investment Advisers LLC acquired a new stake in shares of Visterra during the 3rd quarter valued at about $27,000. Finally, Dean Capital Investments Management LLC acquired a new stake in shares of Visterra during the 3rd quarter valued at about $341,000.
Visterra Company Profile
Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company’s technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for Visterra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visterra and related companies with MarketBeat.com's FREE daily email newsletter.